UBS Turns More Bullish on Gilead Sciences, Inc. (GILD) Amid Positive Pharma Sector Outlook

Company Overview - Gilead Sciences, Inc. is a California-based biopharmaceutical company founded in 1987, specializing in medicines aimed at unmet needs, including treatments for HIV/AIDS, COVID-19, viral hepatitis, oncology, pulmonary arterial hypertension, and serious invasive fungal infections [4] Investment Ratings and Price Targets - UBS raised the price target on Gilead Sciences from $145 to $155, maintaining a Buy rating, which implies nearly a 12% upside from the current price [1] - BMO Capital also increased its target on Gilead Sciences to $150 from $135, reiterating an Outperform rating, and highlighted the strong momentum in the company's HIV business and the successful launch of Yeztugo, which is projected to achieve $150 million in FY25 sales [3] Industry Insights - The U.S. Pharmaceuticals and Biotechnology group is expected to perform strongly due to appealing valuations, light positioning, and sustained pharma-led M&A activity, despite concerns regarding conservative guidance [2]